MBX Biosciences (NASDAQ:MBX) Sets New 12-Month High - Here's Why

Key Points

• MBX Biosciences hit a new 52-week high, trading as high as $66.66 before easing to $61.10, reflecting strong recent momentum in the stock.
• Analyst sentiment is generally positive, with multiple firms raising price targets and the stock carrying a consensus “Moderate Buy” rating and average target of $66.75.
• Institutional investors have been building positions, including a major increase by Stempoint Capital and notable stake additions from other large funds.

MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $66.66 and last traded at $61.10, with a volume of 107404 shares changing hands. The stock had previously closed at $63.57.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Truist Financial raised their price target on MBX Biosciences from $50.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Citigroup reiterated an "outperform" rating on shares of MBX Biosciences in a report on Tuesday, May 12th. Citizens Jmp increased their target price on MBX Biosciences from $76.00 to $86.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 12th. Stifel Nicolaus set a $56.00 target price on MBX Biosciences in a research report on Tuesday, May 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of MBX Biosciences in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, MBX Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $66.75.

MBX Biosciences Trading Down 3.1%

The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -27.81 and a beta of 0.16. The stock's fifty day simple moving average is $44.81 and its 200-day simple moving average is $37.72.

Institutional Investors Weigh In On MBX Biosciences

Several large investors have recently bought and sold shares of the stock. Stempoint Capital LP raised its position in MBX Biosciences by 535.8% in the 1st quarter. Stempoint Capital LP now owns 499,469 shares of the company's stock valued at $14,909,000 after purchasing an additional 420,916 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in MBX Biosciences in the first quarter valued at approximately $308,000. California State Teachers Retirement System lifted its stake in MBX Biosciences by 1,197.9% in the first quarter. California State Teachers Retirement System now owns 22,765 shares of the company's stock worth $680,000 after acquiring an additional 21,011 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in MBX Biosciences by 1.9% in the first quarter. Rock Springs Capital Management LP now owns 287,967 shares of the company's stock worth $8,596,000 after acquiring an additional 5,343 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in MBX Biosciences by 30.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 90,634 shares of the company's stock worth $2,705,000 after acquiring an additional 21,083 shares in the last quarter.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.